Viking Therapeutics and Roche Report Positive Trial Data on Obesity Drugs
· Business · Yahoo Finance, Barron's
Viking Therapeutics and Roche have both reported positive trial results for their respective obesity treatments. Viking Therapeutics announced that its GLP1/GIP agonist drug, VK2735, delivered placebo-adjusted weight loss over a 33-week period. Shares of Viking Therapeutics surged in premarket trading following the announcement. Meanwhile, weight-loss drug market leaders Eli Lilly and Novo Nordisk saw their shares fall slightly.
Why it matters
The positive trial data intensifies competition in the lucrative global weight-loss drug market, directly challenging established leaders Eli Lilly and Novo Nordisk.
Read the original report — Yahoo Finance
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.